UNSPSC 51162734: Pseudoephedrine

This classification denotes an alpha-adrenergic agonist with the molecular formula C10H15NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 7CUC9DDI9F, chemically known as 1s,2s-(+)-pseudoephedrine hydrochloride but more generally known as pseudoephedrine, which bears US NIH Compound Identifier 5032. European Medicines Agency schedules Pseudoephedrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10157MIG.

UNSPSC 51162734 Pseudoephedrine is a Commodity code that frames pharmaceuticals and over-the-counter products state and local governments actually buy under broader pharmaceutical procurement vehicles. Recent solicitations show activity split between naloxone and drug deactivation systems for emergency response and community health, and multi-source generic pharmaceuticals distributed through cooperative purchasing agreements. Issuing bodies span county health departments, state procurement offices, and multistate cooperative purchasing alliances. Seminole County, Florida issued an IFB in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding with quarterly deliveries, while the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP in January 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities including Oregon. Both procurements required vendors to certify compliance with pharmaceutical manufacturing standards, maintain insurance coverage, and demonstrate pricing flexibility or fixed costs over multi-year terms.

Geographic activity centers on Florida and Minnesota with cross-state reach through the MMCAP cooperative vehicle extending to Oregon. The Seminole County naloxone procurement (IFB60459723LAS, response due July 26, 2023) targets community health facilities, while the MMCAP RFP (S1070000015802, response due March 26, 2026) distributes generic pharmaceuticals across multiple member jurisdictions through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with awards effective July 1, 2026. The MMCAP evaluation weights price competitiveness at 75 percent, with compliance to cGMP and Drug Supply Chain Security Act requirements mandatory and administrative fees of 3 percent assessed on all contract purchases.